Navigation Links
FDA Approves Vaccines for 2009 H1N1 Influenza Virus
Date:9/15/2009

Approval Provides Important Tool to Fight Pandemic

WASHINGTON, Sept. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

"Today's approval is good news for our nation's response to the 2009 H1N1 influenza virus," said Commissioner of Food and Drugs Margaret A. Hamburg, M.D. "This vaccine will help protect individuals from serious illness and death from influenza."

The vaccines are made by CSL Limited, MedImmune LLC, Novartis Vaccines and Diagnostics Limited, and sanofi pasteur Inc. All four firms manufacture the H1N1 vaccines using the same processes, which have a long record of producing safe seasonal influenza vaccines.

"The H1N1 vaccines approved today undergo the same rigorous FDA manufacturing oversight, product quality testing and lot release procedures that apply to seasonal influenza vaccines," said Jesse Goodman, M.D., FDA acting chief scientist.

Based on preliminary data from adults participating in multiple clinical studies, the 2009 H1N1 vaccines induce a robust immune response in most healthy adults eight to 10 days after a single dose, as occurs with the seasonal influenza vaccine.

Clinical studies under way will provide additional information about the optimal dose in children. The recommendations for dosing will be updated if indicated by findings from those studies. The findings are expected in the near future.

As with the seasonal influenza vaccines, the 2009 H1N1 vaccines are being produced in formulations that contain thimerosal, a mercury-containing preservative, and in formulations that do not contain thimerosal.

People with severe or life-threatening allergies to chicken eggs, or to any other substance in the vaccine, should not be vaccinated.

In the ongoing clinical studies, the vaccines have been well tolerated. Potential side effects of the H1N1 vaccines are expected to be similar to those of seasonal flu vaccines.

For the injected vaccine, the most common side effect is soreness at the injection site. Other side effects may include mild fever, body aches, and fatigue for a few days after the inoculation. For the nasal spray vaccine, the most common side effects include runny nose or nasal congestion for all ages, sore throats in adults, and -- in children 2 to 6 years old -- fever.

As with any medical product, unexpected or rare serious adverse events may occur. The FDA is working closely with governmental and nongovernmental organizations to enhance the capacity for adverse event monitoring, information sharing and analysis during and after the 2009 H1N1 vaccination program. In the U.S. Department of Health and Human Services, these agencies include the Centers for Disease Control and Prevention.

Vaccines against three seasonal virus strains are already available and should be used (see information on the seasonal flu). However, they do not protect against the 2009 H1N1 virus (see information on H1N1 flu).

    Media Inquiries: Pat El-Hinnawy, 301-796-4763,
     patricia.el-hinnawy@fda.hhs.gov;
    Peper Long, 301-796-4671, mary.long@fda.hhs.gov
    Consumer Inquiries: 1-888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... Butch of CertainTeed Corporation, he knew it was something that contractors should have ... and cutting-edge as it gets,” says Butch, CertainTeed’s Director of Contractor Programs. ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Effective leaders not ... and the industry as a whole. On June 2, Northbound CEO Mike Neatherton and ... Disorders (WCSAD) and presenting the opening plenary on “Leadership: The Journey to Authenticity” with ...
(Date:5/31/2016)... ... May 31, 2016 , ... WaterField Designs, an innovative leader in ... waxed-canvas and leather Duo Dopp Kit , the ideal gift upgrade for Dad ... the Duo is smartly designed for Dad’s grooming routine. Two compartments keep ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Interest is ... primary screening tool and as an orthogonal tool for RNAi hit validation. A key ... and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. ...
(Date:5/31/2016)... Aviv (PRWEB) , ... May 31, 2016 , ... ... the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 ... and publishes a series of research reports evaluating these innovative vendors and their ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... , May 31, 2016   Plexus Technology ... of anesthesia information management systems (AIMS), is pleased ... as Vice President of Technology. In this ... all aspects of the company,s technological development. He ... customers to determine the expansion of new products, ...
(Date:5/31/2016)... , May 31, 2016 ... and Annotate Content From Elsevier,s ScienceDirect Database ... scientific, technical and medical information products and services, ... Berlin -based scientific collaboration platform PaperHive to enable ... over 12 million articles on ScienceDirect , ...
(Date:5/31/2016)... , May 31, 2016 ... World Health Assembly zur Eliminierung von viraler Hepatitis ... Mitgliedsstaaten eine historische Verpflichtung eingegangen, virale Hepatitis bis ... . World Health Assembly haben sich die ... bzgl. viraler Hepatitis (Global Viral Hepatitis Strategy) zu ...
Breaking Medicine Technology: